A new targeted radiation drug for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new radioactive drug (161Tb-SibuDAB) for men with metastatic prostate cancer that has grown despite standard treatments. It aims to find the right dose and see if it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced prostate cancer that has spread and is no longer responding to hormone therapy or chemotherapy.
- You have at least 3 measurable tumors on a PSMA PET scan with strong PSMA activity.
- You are in good general health (ECOG score 0 or 1).
- Your blood counts and kidney/liver function are within acceptable ranges.
- You have not had prior PSMA-targeted radiation therapy (except for two cycles of standard treatment in part of the study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
This study tests a new experimental treatment for advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The treatment is a radioactive drug that targets a protein called PSMA on cancer cells, aiming to deliver radiation directly to the tumor.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
This study tests a new radioactive drug (177Lu-PSMA-137) that targets a marker on prostate cancer cells called PSMA. It aims to see if this treatment is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
Hear when a new Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.